Optimizing therapy with 6-mercaptopurine and azathioprine: to measure or not to measure?

Bowen, G.E. , Irons, G.V. , Rhodes, J.B. and Kirsner, J.B. ( 1966) Early experiences with azathioprine in ulcerative colitis: a note of caution. JAMA 195: 460-464.

Burchenal, J.H. , Murphy, M.L. , Ellison, R.R. , Sykes, M.P. , Tan, T.C. , Leone, L.A. et al. (1953) Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukaemia and allied diseases. Blood 8: 965-999.

Colombel, J.F. , Ferrari, N. , Debuysere, H. , Marteau, P. , Gendre, J.P. , Bonaz, B. et al. (2000) Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn’s disease and severe myelosuppression during azathioprine therapy. Gastroenterology 118: 1025-1030.

Cuffari, C. , Dassopoulos, T. , Turnbough, L. , Thompson, R.E. and Bayless, T.M. ( 2004) Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol 2: 410-417.

Dubinsky, M.C. , Lamothe, S. , Yang, H.Y. , Targan, S.R. , Sinnett, D. , Theoret, Y. et al. (2000) Pharmacogenetics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118: 705-713.

Dubinsky, M.C. , Reyes, E. , Ofman, J. , Chiou, C.F. , Wade, S. and Sandborn, W.J. ( 2005) A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol 100: 2239-2247.

Dubinsky, M.C. , Yang, H. , Hassard, P.V. , Seidman, E.G. , Kam, L.Y. , Abreu, M.T. et al. (2002) 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease . Gastroenterology 122: 904-915.

Elion, G.B. and Hitchings, G.H. ( 1975) Azathioprine, In: Evenson, M.A. (ed.), Handbook of Experimental Pharmacology, Springer-Verlag: New York.

Hitchings, G.H. , Elion, G.B. , Falco, E.A. , Russell, P.B. and Vanderwerff, H. ( 1950) Studies on analogs of purines and pyrimidines. Ann N Y Acad Sci 52: 1318-1335.

Lennard, L. ( 1992) The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 43: 329-339.

Lennard, L. , Rees, C.A. , Lilleyman, J.S. and Maddocks, J.L. ( 1983) Childhood leukemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia. Br J Clin Pharmacol 16: 359-363.

Lennard, L. , Van Loon, J.A. , Lilleyman, J.S. and Weinshilboum, R.M. ( 1987) Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther 41: 18-25.

Lewis, J.D. , Abramson, O. , Pascua, M. , Liu, L. , Asakura, L.M. , Velayos, F.S. et al. (2009) Timing of myelosuppression during thiopurine therapy for inflammatory bowel disease: implications for monitoring recommendations. Clin Gastroenterol Hepatol 7: 1195-1201.

Osterman, M.T. , Kundu, R. , Lichtenstein, G.R. and Lewis, J.D. ( 2006) Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 130: 1047-1053.

Present, D.H. , Korelitz, B.I. , Wisch, N. , Glass, J.L. , Sachar, D.B. and Pasternack, B.S. ( 1980) Treatment of Crohn’s disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 302: 981-987.

Shaye, O.A. , Yadegari, M. , Abreu, M.T. , Poordad, F. , Simon, K. , Simon, K. et al. (2007) Hepatotoxicity of 6-mercaptopurine (6-MP) and Azathioprine (AZA) in adult IBD patients. Am J Gastroenterol 102: 2488-2494.

Sparrow, M.P. , Hande, S.A. , Friedman, S. , Cao, D. and Hanauer, S.B. ( 2007) Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol 5: 209-214.

Sparrow, M.P. , Hande, S.A. , Friedman, S. , Lim, W.C. , Reddy, S.I. , Cao, D. et al. (2005) Allopurinol safely and effectively optimizes thioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther 22: 441-446.

Tiede, I. , Fritz, G. , Strand, S. , Poppe, D. , Dvorsky, R. , Strand, D. et al. (2003) CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 111: 1133-1145.

van Asseldonk, D.P. , Kanis, B.M. , de Boer, N.K. and van Bodegraven, A.A. (2009) Leukopenia due to parvovirus B19 in a Crohn’s disease patient using azathioprine. Digestion 79: 211-214.

Weinshilboum, R.M. and Sladek, S.L. ( 1980) Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methytransferase activity. Am J Hum Genet 32: 651-662.

Willoughby, J.T. , Beckett, J. , Kumar, P.J. and Dawson, A.M. ( 1971) Controlled trial of azathioprine in Crohn’s disease . Lancet 298: 944-947.

Winter, J. , Walker, A. , Shapiro, D. , Gaffney, D. , Spooner, R.J. and Mills, P.R. ( 2004) Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 20: 593-599.

Winter, J.W. , Gaffney, D. , Shapiro, D. , Spooner, R.J. , Marinaki, A.M. , Sanderson, A.M. et al. (2007) Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 25: 1069-1077.